雷贝拉唑在急性心肌梗死患者经皮冠状动脉介入术后预防消化道出血的效果分析

Effect Analysis of Rabeprazole in Prevention of Alimentary Tract Hemorrhage of Patients with Acute Myocardial infarction after Percutaneous Coronary Intervention

目的观察雷贝拉唑用于减少急性心肌梗死患者术后消化道出血的临床疗效。方法纳入2014年1月—2015年6月桂林市人民医院收治的急性心肌梗死患者120例,按用药方法将其分为治疗组和对照组,每组60例。所有患者均行经皮冠状动脉介入治疗,对照组给予阿司匹林和替格瑞洛治疗,治疗组在对照组基础上给予雷贝拉唑治疗。对比两组术后4周内消化道出血发生率,分析两组治疗前后不同时点的血小板计数(blood platelet,PLT)、外周血红细胞计数(red blood cell,RBC)和血红蛋白(hemoglobin,Hb)水平变化。结果治疗组术后4周内消化道出血发生率显著低于对照组(P<0.05)。术后2周和4周,治疗组PLT、RBC和Hb水平均高于对照组(P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论雷贝拉唑可减少急性心肌梗死患者经皮冠状动脉介入治疗术后消化道出血的风险,效果明显,且不良反应少。

Objective To observe clinical efficacy of Rabeprazole in prevention of alimentary tract hemorrhage of patients with acute myocardial infarction after percutaneous coronary intervention （PCI）. Methods A total of 120 patients with acute myocardial infarction admitted during January 2014 and June 2015 were divided into treatment group and control group （ n = 60 for each group） according medication methods. All patients received PCI treatment, and then con- trol group received Aspirin and Ticagrelor treatments, while treatment group was added Rabeprazole on the basis of treatment for control group. In two groups, ratio of patients having alimentary tract hemorrhage was compared, and changes of blood platelet count （ BPC）, red blood cell （ RBC ） and hemoglobin （Hb） levels in peripheral blood at different time points before and after treatment were analyzed. Results Incidence rate of patients having alimentary tract hemorrhage in postoperative 4 weeks in treatment group was significantly lower than that in control group （P 〈 0. 05 ）. In postoperative 2 weeks and 4 weeks, PLT, RBC and lib levels in treatment group were significantly higher than those in control group （P 〈 0. 05）. There was no significant difference in total incidence of adverse reactions between the two groups （ P 〉 0.05）. Conclusion Rabeprazole treatment can effectively reduce ratio of patients having alimentary tract hemorrhage in patients with acute myocardial infarction after percutaneous coronary intervention, and its effect is obvious with less adverse reactions.